



US 20060014243A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2006/0014243 A1****Li** (43) **Pub. Date: Jan. 19, 2006**(54) **HUMAN G-PROTEIN CHEMOKINE
RECEPTOR HSATU68****Publication Classification**(75) Inventor: **Yi Li**, Sunnyvale, CA (US)(51) **Int. Cl.****C07K 14/715** (2006.01)**C07H 21/04** (2006.01)**C12P 21/06** (2006.01)

Correspondence Address:

**HUMAN GENOME SCIENCES INC
INTELLECTUAL PROPERTY DEPT.
14200 SHADY GROVE ROAD
ROCKVILLE, MD 20850 (US)**(52) **U.S. Cl.** **435/69.1**; 435/320.1; 435/325;
530/350; 536/23.5; 435/455(73) Assignee: **Human Genome Sciences, Inc.**, Rock-
ville, MD(57) **ABSTRACT**(21) Appl. No.: **11/017,058**(22) Filed: **Dec. 21, 2004****Related U.S. Application Data**(63) Continuation of application No. 09/101,518, filed on
Dec. 21, 1998, now abandoned, filed as 371 of
international application No. PCT/US96/00499, filed
on Jan. 11, 1996.

Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the under-expression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.

FIG. 1A

10 30 50
 CCTGAAGGGAGAGCAGGGAGAGAGAGGACAGTGGCCAGAGAGGGCTCTGGGCACTGGAGG
 70 90 110
 GACGCTCTTCTTCCTGCCCAGGGGTCCCTGGGCGGATGGGATCACGCAGAAGAATGCGAG
 130 150 170
 AGAAGCAGCCTTTGAGAAGGGAAGTCACTATCCCAGAGCCCAGACTGAGCGGATGGAGTT
 M E L
 190 210 230
 GAGGAAGTACGGCCCTGGAAGACTGGCGGGGACAGTTATAGGAGGAGCTGCTCAGAGTAA
 R K Y G P G R L A G T V I G G A A Q S K
 250 270 290
 ATCACAGACTAAATCAGACTCAATCACAAAAGAGTTCCTGCCAGGCCTTTACACAGCCCC
 S Q T K S D S I T K E F L P G L Y T A P
 310 330 350
 TTCCTCCCCGTTCCCGCCCTCACAGGTGAGTGACCACCAAGTGCTAAATGACGCCGAGGT
 S S P F P P S Q V S D H Q V L N D A E V
 370 390 410
 TGCCGCCCTCCTGGAGAACTTCAGCTCTTCCTATGACTATGGAGAAAACGAGAGTGA CTC
 A A L L E N F S S S Y D Y G E N E S D S
 430 450 470
 GTGCTGTACCTCCCCGCCCTGCCACAGGACTTCAGCCTGAACTTCGACCGGGCCTTCCT
 C C T S P P C P Q D F S L N F D R A F L

FIG. 1B

490 510 530
GCCAGCCCTCTACAGCCTCCTCTTTCTGCTGGGGCTGCTGGGCAACGGCGCGGTGGCAGC
P A L Y S L L F L L G L L G N G A V A A
550 570 590
CGTGCTGCTGAGCCGGCGGACAGCCCTGAGCAGCACCGACACCTTCCTGCTCCACCTAGC
V L L S R R T A L S S T D T F L L H L A
610 630 650
TGTAGCAGACACGCTGCTGGTGCTGACACTGCCGCTCTGGGCAGTGGACGCTGCCGTCCA
V A D T L L V L T L P L W A V D A A V Q
670 690 710
GTGGGTCTTTGGCTCTGGCCTCTGCAAAGTGGCAGGTGCCCTCTTCAACATCAACTTCTA
W V F G S G L C K V A G A L F N I N F Y
730 750 770
CGCAGGAGCCCTCCTGCTGGCCTGCATCAGCTTTGACCGCTACCTGAACATAGTTCATGC
A G A L L L A C I S F D R Y L N I V H A
790 810 830
CACCCAGCTCTACCGCCGGGGGGCCCCCGGCCGCGTGACCCTCACCTGCCTGGCTGTCTG
T Q L Y R R G P P A R V T L T C L A V W
850 870 890
GGGGCTCTGCCTGCTTTTCGCCCTCCCAGACTTCATCTTCCTGTCGGCCCACACGACGA
G L C L L F A L P D F I F L S A H H D E

FIG. 1C

910 930 950
GCGCCTCAACGCCACCCACTGCCAATACTTCCCACAGGTGGGCGCACGGCTCTGCG
R L N A T H C Q Y N F P Q V G R T A L R
970 990 1010
GGTGCTGCAGCTGGTGGCTGGCTTTCTGCTGCCCCTGCTGGTCATGGCCTACTGCTATGC
V L Q L V A G F L L P L L V M A Y C Y A
1030 1050 1070
CCACATCCTGGCCGTGCTGCTGGTTTCCAGGGGCCAGCGGCGCCTGCGGGCCATGCGGGCT
H I L A V L L V S R G Q R R L R A M R L
1090 1110 1130
GGTGGTGGTGGTCGTGGTGGCCTTTGCCCTCTGCTGGACCCCCTATCACCTGGTGGTGCT
V V V V V V A F A L C W T P Y H L V V L
1150 1170 1190
GGTGGACATCCTCATGGACCTGGGCGCTTTGGCCCGCAACTGTGGCCGAGAAAGCAGGGT
V D I L M D L G A L A R N C G R E S R V
1210 1230 1250
AGACGTGGCCAAGTCGGTCACCTCAGGCCTGGGCTACATGCACTGCTGCCTCAACCCGCT
D V A K S V T S G L G Y M H C C L N P L
1270 1290 1310
GCTCTATGCCTTTGTAGGGGTCAAGTTCCGGGAGCGGATGTGGATGCTGCTCTTGCGCCT
L Y A F V G V K F R E R M W M L L L R L

FIG. 1D

1330 1350 1370
GGGCTGCCCCAACCAGAGAGGGCTCCAGAGGCAGCCATCGTCTTCCCGCCGGGATTCATC
G C P N Q R G L Q R Q P S S S R R D S S
1390 1410 1430
CTGGTCTGAGACCTCAGAGGCCTCCTACTCGGGCTTGTGAGGCCGGAATCCGGGCTCCCC
W S E T S E A S Y S G L *
1450 1470 1490
TTTCGCCCACAGTCTGACTTCCCCGCATTCCAGGCTCCTCCCTCCCTCTGCCGGCTCTGG
1510 1530 1550
CTCTCCCCAATATCCTCGCTCCCGGGACTCACTGGCAGCCCCAGCACCACCAGGTCTCCC
1570 1590 1610
GGGAAGCCACCCTCCCAGCTCTGAGGACTGCACCATTGCTGCTCCTTAGCTGCCAAGCCC
1630 1650 1670
CATCCTGCCGCCCCGAGGTGGCTGCCTGGAGCCCCACTGCCCTTCTCATTTGGAAACTAAA
1690 1710 1730
ACTTCATCTTCCCCAAGTGCGGGGAGTACAAGGCATGGCGTAGAGGGTGCTGCCCCATGA
1750 1770 1790
AGCCACAGCCCAGGCCTCCAGCTCAGCAGTGACTGTGGCCATGGTCCCCAAGACCTCTAT
1810 1830 1850
ATTTGGTCTTTTATTTTATGTCTAAAATCCTGCTTAAACTTTTCAATAAACAAGATCG
1870
TCAGGAAAAAAAAAAAA

FIG. 2A

54	DHQVLNDAEVAALLENFSSSYDYGENESDSCCTSPPCPQDFSLNFDRAFL	103
	: :::: :. .: ::: :	
2	ESDSFEDFWKGEDLSNYSYSSTLPPFLLDAAPCEPE.....SLEINKYFV	46
104	PALYSLLFLLGLLGNGAVAAVLLSRRTALSSTDTFLLHLAVADTLLVLT	153
	. : . : : : : . .: .: : :.	
47	VIIYALVFLLSLLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALT	96
154	PLWAVDAAVQWVFGSGLCKVAGALFNINFYAGALLACISFDRYLNIVHA	203
	: .. . : . .: :: . . .	
97	PIWAASKVNGWIFGTFLCKVVSLLKEVNFYSGILLACISVDRYLAIVHA	146
204	TQLYRRGPPARVTLTCLAVWGLCLLFALPDFIFLSAHHDERLNATHCQYN	253
: .: : : :: :	
147	TRTLTQ.KRYLVKFICLSIWGLSLLLALPVLLFRRTVYSSNVSPACYEDM	195
254	FPQVG..RTALRVLQLVAGFLLPLLVMAYCYAHILAVLLVSRGQRRRLRAM	301
	..: : . : : : : . . : .: .:	
196	GNNTANWRMLLRILPQSFGFIVPLLIMLFCYGFTLRTLKFAHMGQKHRAM	245

FIG. 2B

302	RLVVVVVAFALCWTPYHLVVLVDILMDLGALARNCGRESRVDVAKSVTS	351
	::.. : : : : ::: .. .	
246	RVIFAVVLIFLLCWLPLYNLVLLADTLMRTQVIQETCERRNHIDRALDATE	295
352	GLGYMHCCLNPLLYAFVGVKFRERMWMLLLRLGCPNQRLQRQPSSSRD	401
	.: : : : . ::.: .. : :::.... :	
296	ILGILHSCLNPLIYAFIGQKFRHGLLKILAIHGLISKDSLPKDSRPSFVG	345
402	SSWSETSEA	410
	.:.. ..	
346	SSSGHTSTT	254

HUMAN G-PROTEIN CHEMOKINE RECEPTOR HSATU68

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of of U.S. application Ser. No. 09/101,518, filed Dec. 21, 1998, which is the National Stage of International Application No. PCT/US96/00499, filed Jan. 11, 1996, all of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

[0002] This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as are vectors, host cells, and recombinant and synthetic methods for producing the same. More particularly, the polypeptides of the present invention are human 7-transmembrane receptors, which have been putatively identified as chemokine receptors, sometimes hereinafter referred to as "G-Protein Chemokine Receptor" or "HSATU68". The invention also relates to screening methods for identifying molecules that inhibit or activate the action of such polypeptides. The invention also relates to diagnostic and therapeutic methods using nucleic acid molecules and/or polypeptides of a G-protein chemokine receptor of the present invention.

[0003] It is well established that many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers, e.g., cAMP (Lefkowitz, *Nature*, 351:353-354 (1991)). Herein these proteins are referred to as proteins participating in pathways with G-proteins or PPG proteins. Some examples of these proteins include the GPC receptors, such as those for adrenergic agents and dopamine (Kobilka, B. K., et al., *PNAS*, 84:46-50 (1987); Kobilka, B. K., et al., *Science*, 238:650-656 (1987); Bunzow, J. R., et al., *Nature*, 336:783-787 (1988)), G-proteins themselves, effector proteins, e.g., phospholipase C, adenylyl cyclase, and phosphodiesterase, and actuator proteins, e.g., protein kinase A and protein kinase C (Simon, M. I., et al., *Science*, 252:802-8 (1991)).

[0004] For example, in one form of signal transduction, the effect of hormone binding is activation of an enzyme, adenylate cyclase, inside the cell. Enzyme activation by hormones is dependent on the presence of the nucleotide GTP, and GTP also influences hormone binding. A G-protein connects the hormone receptors to adenylate cyclase. G-protein was shown to exchange GTP for bound GDP when activated by hormone receptors. The GTP-carrying form then binds to an activated adenylate cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein itself, returns the G-protein to its basal, inactive form. Thus, the G-protein serves a dual role, as an intermediate that relays the signal from receptor to effector, and as a clock that controls the duration of the signal.

[0005] The membrane protein gene superfamily of G-protein coupled receptors has been characterized as having seven putative transmembrane domains. The domains are believed to represent transmembrane α -helices connected by extracellular or cytoplasmic loops. G-protein coupled receptors include a wide range of biologically active receptors, such as hormone, viral, growth factor and neuroreceptors.

[0006] G-protein coupled receptors have been characterized as including these seven conserved hydrophobic stretches of about 20 to 30 amino acids, connecting at least eight divergent hydrophilic loops. The G-protein family of coupled receptors includes dopamine receptors, which bind to neuroleptic drugs used for treating psychotic and neurological disorders. Other examples of members of this family include calcitonin, adrenergic, endothelin, cAMP, adenosine, muscarinic, acetylcholine, serotonin, histamine, thrombin, kinin, follicle stimulating hormone, opsins, endothelial differentiation gene-1 receptor and rhodopsins, odorant, cytomegalovirus receptors, etc.

[0007] G-protein coupled receptors can be intracellularly coupled by heterotrimeric G-proteins to various intracellular enzymes, ion channels and transporters (see, Johnson et al., *Endoc. Rev.*, 10:317-331 (1989)). Different G-protein α -subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phosphorylation of cytoplasmic residues of G-protein coupled receptors has been identified as an important mechanism for the regulation of G-protein coupling of some G-protein coupled receptors. G-protein coupled receptors are found in numerous sites within a mammalian host.

[0008] Chemokines, also referred to as intercrine cytokines, are a subfamily of structurally and functionally related cytokines. These molecules are 8-10 kd in size. In general, chemokines exhibit 20% to 75% homology at the amino acid level and are characterized by four conserved cysteine residues that form two disulfide bonds. Based on the arrangement of the first two cysteine residues, chemokines have been classified into two subfamilies, alpha and beta. In the alpha subfamily, the first two cysteines are separated by one amino acid and hence are referred to as the "C-X-C" subfamily. In the beta subfamily, the two cysteines are in an adjacent position and are, therefore, referred to as the "C-C" subfamily. Thus far, at least nine different members of this family have been identified in humans.

[0009] The intercrine cytokines exhibit a wide variety of functions. A hallmark feature is their ability to elicit chemotactic migration of distinct cell types, including monocytes, neutrophils, T lymphocytes, basophils and fibroblasts. Many chemokines have pro-inflammatory activity and are involved in multiple steps during an inflammatory reaction. These activities include stimulation of histamine release, lysosomal enzyme and leukotriene release, increased adherence of target immune cells to endothelial cells, enhanced binding of complement proteins, induced expression of granulocyte adhesion molecules and complement receptors, and respiratory burst. In addition to their involvement in inflammation, certain chemokines have been shown to exhibit other activities. For example, macrophage inflammatory protein 1 (MIP-1) is able to suppress hematopoietic stem cell proliferation, platelet factor-4 (PF-4) is a potent inhibitor of endothelial cell growth, Interleukin-8 (IL-8) promotes proliferation of keratinocytes, and GRO is an autocrine growth factor for melanoma cells.

[0010] In light of the diverse biological activities, it is not surprising that chemokines have been implicated in a number of physiological and disease conditions, including lymphocyte trafficking, wound healing, hematopoietic regulation and immunological disorders such as allergy, asthma and arthritis.

SUMMARY OF THE INVENTION

[0011] In accordance with one aspect of the present invention, there are provided novel mature receptor polypeptides as well as biologically active and diagnostically or therapeutically useful fragments, analogs and derivatives thereof. The receptor polypeptides of the present invention are of human origin.

[0012] In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules encoding the receptor polypeptides of the present invention, including mRNAs, cDNAs, genomic DNA as well as antisense analogs thereof and biologically active and diagnostically or therapeutically useful fragments thereof.

[0013] In accordance with another aspect of the present invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressed by the human cDNA contained in ATCC Deposit No. 97334.

[0014] In accordance with a further aspect of the present invention, there are provided processes for producing such receptor polypeptides by recombinant techniques comprising culturing recombinant prokaryotic and/or eukaryotic host cells, containing nucleic acid sequences encoding the receptor polypeptides of the present invention, under conditions promoting expression of said polypeptides and subsequent recovery of said polypeptides.

[0015] In accordance with yet a further aspect of the present invention, there are provided antibodies against such receptor polypeptides.

[0016] In accordance with another aspect of the present invention there are provided methods of screening for compounds that bind to and activate or inhibit activation of the receptor polypeptides of the present invention.

[0017] In accordance with still another embodiment of the present invention there are provided processes of administering compounds to a host which bind to and activate the receptor polypeptide of the present invention which are useful in stimulating haematopoiesis, wound healing, coagulation, angiogenesis, to treat tumors, chronic infections, leukemia, T-cell mediated auto-immune diseases, parasitic infections, psoriasis, and to stimulate growth factor activity.

[0018] In accordance with another aspect of the present invention there is provided a method of administering the receptor polypeptides of the present invention via gene therapy to treat conditions related to underexpression of the polypeptides or underexpression of a ligand for the receptor polypeptide.

[0019] In accordance with still another embodiment of the present invention there are provided processes of administering compounds to a host which bind to and inhibit activation of the receptor polypeptides of the present invention which are useful in the prevention and/or treatment of allergy, atherogenesis, anaphylaxis, malignancy, chronic and acute inflammation, histamine and IgE-mediated allergic reactions, prostaglandin-independent fever, bone marrow failure, silicosis, sarcoidosis, rheumatoid arthritis, shock and hyper-eosinophilic syndrome.

[0020] In accordance with yet another aspect of the present invention, there are provided nucleic acid probes comprising nucleic acid molecules of sufficient length to specifically hybridize to the polynucleotide sequences of the present invention.

[0021] In accordance with still another aspect of the present invention, there are provided diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences encoding such polypeptides and for detecting an altered level of the soluble form of the receptor polypeptides.

[0022] In accordance with yet a further aspect of the present invention, there are provided processes for utilizing such receptor polypeptides, or polynucleotides encoding such polypeptides, for in vitro purposes related to scientific research, synthesis of DNA and manufacture of DNA vectors.

[0023] These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims.

[0025] FIGS. 1A-D shows the cDNA sequence (SEQ ID NO:1) and the corresponding deduced amino acid sequence (SEQ ID NO:2) of a G-protein chemokine receptor of the present invention. The standard one-letter abbreviation for amino acids is used. Sequencing was performed using a 373 Automated DNA sequencer (Applied Biosystems, Inc.).

[0026] FIGS. 2A-B illustrates an amino acid alignment of the G-protein chemokine receptor of the present invention (top) (SEQ ID NO:2) and the human interleukin-8 receptor (bottom) (SEQ ID NO:9).

[0027] In accordance with an aspect of the present invention, there is provided an isolated nucleic acid (polynucleotide) which encodes for the mature polypeptide having the deduced amino acid sequence of FIGS. 1A-D (SEQ ID NO:2).

[0028] In accordance with another aspect of the present invention there are provided isolated polynucleotides encoding a mature polypeptide expressed by the human cDNA contained in ATCC Deposit No. 97334, deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209, USA, on Nov. 6, 1995. The deposited material is a cDNA insert, encoding a polypeptide of the present invention, cloned into a pBlue-script SK(-) vector (Stratagene, La Jolla, Calif.), which will confer ampicillin resistance upon transformation.

[0029] The deposit(s) has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for purposes of Patent Procedure. The strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. These deposits are provided merely as convenience to those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. §112. The sequence of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with any description of

sequences herein. A license may be required to make, use or sell the deposited materials, and no such license is hereby granted.

[0030] Polynucleotides of this invention were discovered in a human genomic library derived from human activated T cells. It is structurally related to the G protein-coupled receptor family. It contains an open reading frames encoding a protein of 415 amino acid residues. The proteins exhibits the highest degree of homology at the amino acid level to a human interleukin-8 receptor with 39.31% identity and 58.405% similarity.

[0031] A polynucleotide of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the mature polypeptide may be identical to the coding sequence shown in FIGS. 1A-D (SEQ ID NO:1) which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same mature polypeptide as the DNA of FIGS. 1A-D (SEQ ID NO:1).

[0032] A polynucleotide which encodes for the mature polypeptide of FIGS. 1A-D (SEQ ID NO:2) may include: only the coding sequence for the mature polypeptide; the coding sequence for the mature polypeptide and additional coding sequence such as a transmembrane (TM) or intracellular domain; the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequence, such as introns or non-coding sequence 5' and/or 3' of the coding sequence for the mature polypeptide.

[0033] The present invention further relates to variants of the hereinabove described polynucleotides which encode for fragments, analogs and derivatives of the polypeptide having the deduced amino acid sequence of FIGS. 1A-D (SEQ ID NO:2). The variant of the polynucleotide may be a naturally occurring allelic variant of the polynucleotide or a non-naturally occurring variant of the polynucleotide.

[0034] Thus, the present invention includes polynucleotides encoding the same mature polypeptide as shown in FIGS. 1A-D (SEQ ID NO:2) as well as variants of such polynucleotides which variants encode for a fragment, derivative or analog of the polypeptide of FIGS. 1A-D (SEQ ID NO:2). Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.

[0035] As hereinabove indicated, the polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequence shown in FIGS. 1A-D (SEQ ID NO:1). As known in the art, an allelic variant is an alternate form of a polynucleotide sequence that may have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.

[0036] The polynucleotides may also encode for a soluble form of the G-protein chemokine receptor polypeptide, which is an extracellular portion of the polypeptide that has been cleaved from the TM and intracellular domains of the full-length polypeptide of the present invention.

[0037] The polynucleotides of the present invention may also have the coding sequence fused in frame to a marker

sequence that allows for purification of the polypeptide of the present invention. The marker sequence may be a hexa-histidine tag supplied by a pQE vector (Qiagen) to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., Cell, 37:767 (1984)).

[0038] The term "gene" means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).

[0039] Fragments of the full-length gene of the present invention may be used as a hybridization probe for a cDNA library to isolate the full-length cDNA and to isolate other cDNAs that have a high sequence similarity to the gene or similar biological activity. Probes of this type preferably have at least 15 bases, preferably 30 bases and most preferably, may contain, for example, 50 or more bases. The probe may also be used to identify a cDNA clone corresponding to a full-length transcript and a genomic clone or clones that contain the complete gene including regulatory and promoter regions, exons, and introns. An example of a screen comprises isolating the coding region of the gene by using the known DNA sequence to synthesize an oligonucleotide probe. Labeled oligonucleotides having a sequence complementary to that of the gene of the present invention are used to screen a library of human cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

[0040] The present invention further relates to polynucleotides that hybridize to the hereinabove-described sequences if there is at least 70%, preferably at least 90%, and more preferably at least 95% identity between the sequences. The present invention particularly relates to polynucleotides that hybridize under stringent conditions to the hereinabove-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which either retain substantially the same biological function or activity as the mature polypeptide encoded by the cDNA of FIGS. 1A-D (SEQ ID NO:1).

[0041] Alternatively, the polynucleotide may have at least 15 bases, preferably 30 bases, and more preferably at least 50 bases which hybridize to a polynucleotide of the present invention and which has an identity thereto, as hereinabove described, and which may or may not retain activity. For example, such polynucleotides may be employed as probes for the polynucleotide of SEQ ID NO:1, for example, for recovery of the polynucleotide or as a diagnostic probe or as a PCR primer.

[0042] The present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences if there is at least 70%, preferably at least 90%, and more preferably at least 95% identity between sequences. The present invention particularly relates to polynucleotides which hybridize under stringent conditions

to the hereinabove-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which either retain substantially the same biological function or activity as the mature polypeptide encoded by the cDNA of FIGS. 1A-D (SEQ ID NO:1).

[0043] The present invention further relates to a G-protein chemokine receptor polypeptide which has the deduced amino acid sequence of FIGS. 1A-D (SEQ ID NO:2), as well as fragments, analogs and derivatives of such polypeptide.

[0044] The terms "fragment," "derivative" and "analog" when referring to the polypeptide of FIGS. 1A-D (SEQ ID NO:2), means a polypeptide which either retains substantially the same biological function or activity as such polypeptide, i.e. functions as a G-protein chemokine receptor, or retains the ability to bind the ligand for the receptor, for example, a soluble form of the receptor. An analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide.

[0045] The polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide.

[0046] The fragment, derivative or analog of the polypeptide of FIGS. 1A-D (SEQ ID NO:2) may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide for purification of the polypeptide or (v) one in which a fragment of the polypeptide is soluble, i.e. not membrane bound, yet still binds ligands to the membrane bound receptor. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

[0047] The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

[0048] Thus, the present invention is directed to polynucleotides having at least a 70% identity, preferably at least 90% and more preferably at least a 95% identity to a polynucleotide which encodes the polypeptide of SEQ ID NO:2 and polynucleotides complementary thereto as well as portions thereof, which portions have at least 15 consecutive bases, preferably 30 consecutive bases and more preferably at least 50 consecutive bases and to polypeptides encoded by such polynucleotides.

[0049] As known in the art "similarity" between two polypeptides is determined by comparing the amino acid sequence and conserved amino acid substitutes thereto of the polypeptide to the sequence of a second polypeptide.

[0050] Fragments or portions of the polypeptides of the present invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis, therefore, the fragments may be employed as intermediates for producing the full-length polypeptides. Fragments or portions of the polynucleotides of the present invention may be used to synthesize full-length polynucleotides of the present invention.

[0051] The term "gene" means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region "leader and trailer" as well as intervening sequences (introns) between individual coding segments (exons).

[0052] The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

[0053] The present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.

[0054] Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

[0055] The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotide may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

[0056] The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

[0057] The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the *E. coli*, lac or trp, the phage lambda P_L promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

[0058] In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in *E. coli*.

[0059] The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein.

[0060] As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as *E. coli*, *Streptomyces*, *Salmonella typhimurium*; fungal cells, such as yeast; insect cells such as *Drosophila* and *Spodoptera* Sf9; animal cells such as CHO, COS or Bowes melanoma; adenovirus; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

[0061] More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example. Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.

[0062] Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are PKK232-8 and PCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P_R, P_L and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

[0063] In a further embodiment, the present invention relates to host cells containing the above-described con-

structs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation. (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

[0064] The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.

[0065] Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.

[0066] Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples including the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

[0067] Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), \hat{A} -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

[0068] Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within

the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice.

[0069] As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEMI (Promega Biotec, Madison, Wis., USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

[0070] Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.

[0071] Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

[0072] Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art.

[0073] Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

[0074] The G-protein chemokine receptor polypeptides can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

[0075] The polypeptides of the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.

[0076] The polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to human disease.

[0077] The G-protein chemokine receptors of the present invention may be employed in a process for screening for compounds which activate (agonists) or inhibit activation (antagonists) of the receptor polypeptide of the present invention.

[0078] In general, such screening procedures involve providing appropriate cells which express the receptor polypeptide of the present invention on the surface thereof. Such cells include cells from mammals, yeast, *drosophila* or *E. Coli*. In particular, a polynucleotide encoding the receptor of the present invention is employed to transfect cells to thereby express the G-protein chemokine receptor. The expressed receptor is then contacted with a test compound to observe binding, stimulation or inhibition of a functional response.

[0079] One such screening procedure involves the use of melanophores which are transfected to express the G-protein chemokine receptor of the present invention. Such a screening technique is described in PCT WO 92/01810 published Feb. 6, 1992.

[0080] Thus, for example, such assay may be employed for screening for a compound which inhibits activation of the receptor polypeptide of the present invention by contacting the melanophore cells which encode the receptor with both the receptor ligand and a compound to be screened. Inhibition of the signal generated by the ligand indicates that a compound is a potential antagonist for the receptor, i.e., inhibits activation of the receptor.

[0081] The screen may be employed for determining a compound which activates the receptor by contacting such cells with compounds to be screened and determining whether such compound generates a signal, i.e., activates the receptor.

[0082] Other screening techniques include the use of cells which express the G-protein chemokine receptor (for example, transfected CHO cells) in a system which measures extracellular pH changes caused by receptor activation, for example, as described in Science, volume 246, pages 181-296 (October 1989). For example, compounds may be contacted with a cell which expresses the receptor polypeptide of the present invention and a second messenger response, e.g. signal transduction or pH changes, may be measured to determine whether the potential compound activates or inhibits the receptor.

[0083] Another such screening technique involves introducing RNA encoding the G-protein chemokine receptor into *Xenopus* oocytes to transiently express the receptor. The receptor oocytes may then be contacted with the receptor ligand and a compound to be screened, followed by detection of inhibition or activation of a calcium signal in the case of screening for compounds which are thought to inhibit activation of the receptor.

[0084] Another screening technique involves expressing the G-protein chemokine receptor in which the receptor is linked to a phospholipase C or D. As representative examples of such cells, there may be mentioned endothelial

cells, smooth muscle cells, embryonic kidney cells, etc. The screening may be accomplished as hereinabove described by detecting activation of the receptor or inhibition of activation of the receptor from the phospholipase second signal.

[0085] Another method involves screening for compounds which inhibit activation of the receptor polypeptide of the present invention by determining the inhibition of binding of a labeled ligand to cells which have the receptor on the surface thereof. Such a method comprises transfecting a eukaryotic cell with DNA encoding the G-protein chemokine receptor of the present invention such that the cell expresses the receptor on its surface and contacting the cell with a compound in the presence of a labeled form of a known ligand. The ligand can be labeled, e.g., by radioactivity. The amount of labeled ligand bound to the receptors is measured, e.g., by measuring radioactivity of the receptors. If the compound binds to the receptor as determined by a reduction of labeled ligand which binds to the receptors, the binding of labeled ligand to the receptor is inhibited.

[0086] An antibody may antagonize a G-protein chemokine receptor of the present invention, or in some cases an oligopeptide, which bind to the G-protein chemokine receptor but does not elicit a second messenger response such that the activity of the G-protein chemokine receptors is prevented. Antibodies include anti-idiotypic antibodies which recognize unique determinants generally associated with the antigen-binding site of an antibody. Potential antagonist compounds also include proteins which are closely related to the ligand of the G-protein chemokine receptors, i.e. a fragment of the ligand, which have lost biological function and when binding to the G-protein chemokine receptor elicit no response.

[0087] An antisense construct prepared through the use of antisense technology, may be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes for the mature polypeptides of the present invention, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix—see Lee et al., *Nucl. Acids Res.*, 6:3073 (1979); Cooney et al, *Science*, 241:456 (1988); and Dervan et al., *Science*, 251: 1360 (1991)), thereby preventing transcription and the production of G-protein chemokine receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of mRNA molecules into G-protein coupled receptor (antisense—Okano, *J. Neurochem.*, 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988)). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of G-protein chemokine receptor.

[0088] A small molecule which binds to the G-protein chemokine receptor, making it inaccessible to ligands such that normal biological activity is prevented, for example small peptides or non-peptide antagonists, may also be used to inhibit activation of the receptor polypeptide of the present invention.

[0089] A soluble form of the G-protein chemokine receptor, e.g. a fragment of the receptors, may be used to inhibit activation of the receptor by binding to the ligand to a polypeptide of the present invention and preventing the ligand from interacting with membrane bound G-protein chemokine receptors.

[0090] The compounds which bind to and activate the G-protein chemokine receptors of the present invention may be employed to stimulate haematopoiesis, wound healing, coagulation, angiogenesis, to treat tumors, chronic infections, leukemia, T-cell mediated auto-immune diseases, parasitic infections, psoriasis, and to stimulate growth factor activity.

[0091] The compounds which bind to and inhibit the G-protein chemokine receptors of the present invention may be employed to treat allergy, atherogenesis, anaphylaxis, malignancy, chronic and acute inflammation, histamine and IgE-mediated allergic reactions, prostaglandin-independent fever, bone marrow failure, silicosis, sarcoidosis, rheumatoid arthritis, shock and hyper-eosinophilic syndrome.

[0092] The compounds may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a therapeutically effective amount of the compound and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should suit the mode of administration.

[0093] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the compounds of the present invention may be employed in conjunction with other therapeutic compounds.

[0094] The pharmaceutical compositions may be administered in a convenient manner such as by the topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes. The pharmaceutical compositions are administered in an amount which is effective for treating and/or prophylaxis of the specific indication. In general, the pharmaceutical compositions will be administered in an amount of at least about 10 g/kg body weight and in most cases they will be administered in an amount not in excess of about 8 mg/Kg body weight per day. In most cases, the dosage is from about 10 g/kg to about 1 mg/kg body weight daily, taking into account the routes of administration, symptoms, etc.

[0095] The soluble G-protein chemokine receptor polypeptides and antagonists or agonists which are polypeptides, may also be employed in accordance with the present invention by expression of such polypeptides in vivo, which is often referred to as "gene therapy."

[0096] Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) encoding a polypeptide ex vivo, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such

methods are well-known in the art. For example, cells may be engineered by procedures known in the art by use of a retroviral particle containing RNA encoding a polypeptide of the present invention.

[0097] Similarly, cells may be engineered in vivo for expression of a polypeptide in vivo by, for example, procedures known in the art. As known in the art, a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the present invention may be administered to a patient for engineering cells in vivo and expression of the polypeptide in vivo. These and other methods for administering a polypeptide of the present invention by such method should be apparent to those skilled in the art from the teachings of the present invention. For example, the expression vehicle for engineering cells may be other than a retrovirus, for example, an adenovirus which may be used to engineer cells in vivo after combination with a suitable delivery vehicle.

[0098] Retroviruses from which the retroviral plasmid vectors hereinabove mentioned may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, adenovirus, Myeloproliferative Sarcoma Virus, and mammary tumor virus. In one embodiment, the retroviral plasmid vector is derived from Moloney Murine Leukemia Virus.

[0099] The vector includes one or more promoters. Suitable promoters which may be employed include, but are not limited to, the retroviral LTR; the SV40 promoter; and the human cytomegalovirus (CMV) promoter described in Miller, et al., *Biotechniques*, Vol. 7, No. 9, 980-990 (1989), or any other promoter (e.g., cellular promoters such as eukaryotic cellular promoters including, but not limited to, the histone, pol III, and -actin promoters). Other viral promoters which may be employed include, but are not limited to, adenovirus promoters, thymidine kinase (TK) promoters, and B19 parvovirus promoters. The selection of a suitable promoter will be apparent to those skilled in the art from the teachings contained herein.

[0100] The nucleic acid sequence encoding the polypeptide of the present invention is under the control of a suitable promoter. Suitable promoters which may be employed include, but are not limited to, adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoA1 promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs (including the modified retroviral LTRs hereinabove described); the -actin promoter; and human growth hormone promoters. The promoter also may be the native promoter which controls the genes encoding the polypeptides.

[0101] The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, ψ -2, ψ -AM, PA12, T19-14x, VT-19-17-H2, CRE, CRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in

Miller, *Human Gene Therapy*, Vol. 1, pgs. 5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO_4 precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

[0102] The producer cell line generates infectious retroviral vector particles which include the nucleic acid sequence(s) encoding the polypeptides. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either in vitro or in vivo. The transduced eukaryotic cells will express the nucleic acid sequence(s) encoding the polypeptide. Eukaryotic cells which may be transduced include, but are not limited to, embryonic stem cells, embryonic carcinoma cells, as well as hematopoietic stem cells, hepatocytes, fibroblasts, myoblasts, keratinocytes, endothelial cells, and bronchial epithelial cells.

[0103] The present invention also provides a method for determining whether a ligand not known to be capable of binding to a G-protein chemokine receptor can bind to such receptor which comprises contacting a mammalian cell which expresses a G-protein chemokine receptor with the ligand under conditions permitting binding of ligands to the G-protein chemokine receptor, detecting the presence of a ligand which binds to the receptor and thereby determining whether the ligand binds to the G-protein chemokine receptor. The systems hereinabove described for determining agonists and/or antagonists may also be employed for determining ligands which bind to the receptor.

[0104] This invention also provides a method of detecting expression of a G-protein chemokine receptor polypeptide of the present invention on the surface of a cell by detecting the presence of mRNA coding for the receptor which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with a nucleic acid probe comprising a nucleic acid molecule of at least 10 nucleotides capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding the receptor under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of the receptor by the cell.

[0105] The present invention also provides a method for identifying receptors related to the receptor polypeptides of the present invention. These related receptors may be identified by homology to a G-protein chemokine receptor polypeptide of the present invention, by low stringency cross hybridization, or by identifying receptors that interact with related natural or synthetic ligands and or elicit similar behaviors after genetic or pharmacological blockade of the chemokine receptor polypeptides of the present invention.

[0106] The present invention also contemplates the use of the gene of the present invention as a diagnostic, for example, some diseases result from inherited defective genes. These genes can be detected by comparing the sequences of the defective gene with that of a normal one. Subsequently, one can verify that a "mutant" gene is associated with abnormal receptor activity. In addition, one can insert mutant receptor genes into a suitable vector for expression in a functional assay system (e.g., calorimetric assay, expression on MacConkey plates, complementation

experiments, in a receptor deficient strain of HEK293 cells) as yet another means to verify or identify mutations. Once "mutant" genes have been identified, one can then screen population for carriers of the "mutant" receptor gene.

[0107] Individuals carrying mutations in the gene of the present invention may be detected at the DNA level by a variety of techniques. Nucleic acids used for diagnosis may be obtained from a patient's cells, including but not limited to such as from blood, urine, saliva, tissue biopsy and autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki, et al., *Nature*, 324:163-166 1986) prior to analysis. RNA or cDNA may also be used for the same purpose. As an example, PCR primers complimentary to the nucleic acid of the instant invention can be used to identify and analyze mutations in the gene of the present invention. For example, deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to radio labeled RNA of the invention or alternatively, radio labeled antisense DNA sequences of the invention. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase A digestion or by differences in melting temperatures. Such a diagnostic would be particularly useful for prenatal or even neonatal testing.

[0108] Sequence differences between the reference gene and "mutants" may be revealed by the direct DNA sequencing method. In addition, cloned DNA segments may be used as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. For example, a sequence primer is used with double stranded PCR product or a single stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures with radio labeled nucleotide or by an automatic sequencing procedure with fluorescent-tags.

[0109] Genetic testing based on DNA sequence differences may be achieved by detection of alterations in the electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Sequences changes at specific locations may also be revealed by nucleus protection assays, such RNase and S1 protection or the chemical cleavage method (e.g. Cotton, et al., *PNAS, USA*, 85:4397-4401 1985).

[0110] In addition, some diseases are a result of, or are characterized by changes in gene expression which can be detected by changes in the mRNA. Alternatively, the genes of the present invention can be used as a reference to identify individuals expressing a decrease of functions associated with receptors of this type.

[0111] The present invention also relates to a diagnostic assay for detecting altered levels of soluble form of the G-protein chemokine receptor polypeptides of the present invention in various tissues. Assays used to detect levels of the soluble receptor polypeptides in a sample derived from a host are well known to those of skill in the art and include radioimmunoassays, competitive-binding assays, Western blot analysis and preferably as ELISA assay.

[0112] An ELISA assay initially comprises preparing an antibody specific to antigens of the G-protein chemokine

receptor polypeptides, preferably a monoclonal antibody. In addition a reporter antibody is prepared against the monoclonal antibody. To the reporter antibody is attached a detectable reagent such as radioactivity, fluorescence or in this example a horseradish peroxidase enzyme. A sample is now removed from a host and incubated on a solid support, e.g. a polystyrene dish, that binds the proteins in the sample. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the monoclonal antibody is incubated in the dish during which time the monoclonal antibodies attach to any G-protein chemokine receptor proteins attached to the polystyrene dish. All unbound monoclonal antibody is washed out with buffer. The reporter antibody linked to horseradish peroxidase is now placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to G-protein chemokine receptor proteins. Unattached reporter antibody is then washed out. Peroxidase substrates are then added to the dish and the amount of color developed in a given time period is a measurement of the amount of G-protein chemokine receptor proteins present in a given volume of patient sample when compared against a standard curve.

[0113] The sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

[0114] Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the cDNA is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

[0115] PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include in situ hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.

[0116] Fluorescence in situ hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 50 or 60 bases. For a review of this technique, see Verma et al., *Human Chromosomes: a Manual of Basic Techniques*, Pergamon Press, New York (1988).

[0117] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence

on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

[0118] Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

[0119] With current resolution of physical mapping and genetic mapping techniques, a cDNA precisely localized to a chromosomal region associated with the disease could be one of between 50 and 500 potential causative genes. (This assumes 1 megabase mapping resolution and one gene per 20 kb).

[0120] The polypeptides, their fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. These antibodies can be, for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.

[0121] Antibodies generated against the polypeptides corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptides itself. In this manner, even a sequence encoding only a fragment of the polypeptides can be used to generate antibodies binding the whole native polypeptides. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.

[0122] For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, *Nature*, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96).

[0123] Techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention. Also, transgenic mice may be used to express humanized antibodies to immunogenic polypeptide products of this invention.

[0124] The above-described antibodies may be employed to isolate the polypeptide of the present invention by attachment of the antibody to a solid support and performing affinity chromatography by passing the polypeptide desired to be purified over the column and recovering the purified polypeptide.

[0125] The present invention will be further described with reference to the following examples; however, it is to be understood that the present invention is not limited to such examples. All parts or amounts, unless otherwise specified, are by weight.

[0126] In order to facilitate understanding of the following examples certain frequently occurring methods and/or terms will be described.

[0127] "Plasmids" are designated by a lower case p preceded and/or followed by capital letters and/or numbers. The starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures. In addition, equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan.

[0128] "Digestion" of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan. For analytical purposes, typically 1 μ g of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 μ l of buffer solution. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 μ g of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37 C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion the reaction is electrophoresed directly on a polyacrylamide gel to isolate the desired fragment.

[0129] Size separation of the cleaved fragments is performed using 8 percent polyacrylamide gel described by Goeddel, D. et al., *Nucleic Acids Res.*, 8:4057 (1980).

[0130] "Oligonucleotides" refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.

[0131] "Ligation" refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (Maniatis, T., et al., Id., p. 146). Unless otherwise provided, ligation may be accomplished using known buffers and conditions with 10 units to T4 DNA ligase ("ligase") per 0.5 μ g of approximately equimolar amounts of the DNA fragments to be ligated.

[0132] Unless otherwise stated, transformation was performed as described in the method of Graham, F. and Van der Eb, A., *Virology*, 52:456-457 (1973).

EXAMPLE 1

Bacterial Expression and Purification of HSATU68

[0133] The DNA sequence encoding for HSATU68, ATCC # 97334 is initially amplified using PCR oligonucleotide

primers corresponding to the 5' and sequences of the processed HSATU68 protein (minus the signal peptide sequence) and the vector sequences 3' to the HSATU68 gene. Additional nucleotides corresponding to HSATU68 were added to the 5' and 3' sequences respectively. The 5' oligonucleotide primer has the sequence 5'CGGGATCCTC-CATGGAGTTGAGGAAGTAC 3' (SEQ ID NO:3) contains a BamHI restriction enzyme site followed by 18 nucleotides of HSATU68 coding sequence starting from the presumed terminal amino acid of the protein. The 3' sequence 5'GGCGGATCCCGCTCACAAGCCCGAGTAGGA 3' (SEQ ID NO:4) contains complementary sequences to a BamHI site and is followed by 18 nucleotides of HSATU68 coding sequence. The restriction enzyme sites correspond to the restriction enzyme sites on the bacterial expression vector pQE-9 (Qiagen, Inc., Chatsworth, Calif., 91311). pQE-9 encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter operator (P/O), a ribosome binding site (RBS), a 6-His tag and restriction enzyme sites. pQE-9 was then digested with BamHI. The amplified sequences were ligated into pQE-9 and were inserted in frame with the sequence encoding for the histidine tag and the RBS. The ligation mixture was then used to transform *E. coli* strain M15/rep 4 (Qiagen, Inc.) by the procedure described in Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, (1989). M15/rep4 contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies were selected. Plasmid DNA was isolated and confirmed by restriction analysis. Clones containing the desired constructs were grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells were grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG ("Isopropyl-B-D-thiogalacto pyranoside") was then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression. Cells were grown an extra 3 to 4 hours. Cells were then harvested by centrifugation. The cell pellet was solubilized in the chaotropic agent 6 Molar Guanidine HCl. After clarification, solubilized HSATU68 was purified from this solution by chromatography on a Nickel-Chelate column under conditions that allow for tight binding by proteins containing the 6-His tag (Hochuli, E. et al., J. Chromatography 411:177-184 (1984)). HSATU68 was eluted from the column in 6 molar guanidine HCl pH 5.0 and for the purpose of renaturation adjusted to 3 molar guanidine HCl, 100 mM sodium phosphate, 10 mmolar glutathione (reduced) and 2 mmolar glutathione (oxidized). After incubation in this solution for 12 hours the protein was dialyzed to 10 mmolar sodium phosphate.

EXAMPLE 2

Expression of Recombinant HSATU68 in COS Cells

[0134] The expression of plasmid, HSATU68 HA is derived from a vector pcDNAI/Amp (Invitrogen) containing: 1) SV40 origin of replication, 2) ampicillin resistance gene, 3) *E. coli* replication origin, 4) CMV promoter fol-

lowed by a polylinker region, a SV40 intron and polyadenylation site. A DNA fragment encoding the entire HSATU68 precursor and a HA tag fused in frame to its 3' end was cloned into the polylinker region of the vector, therefore, the recombinant protein expression is directed under the CMV promoter. The HA tag correspond to an epitope derived from the influenza hemagglutinin protein as previously described (I. Wilson, H. Niman, R. Heighten, A. Chersonson, M. Connolly, and R. Lerner, 1984, Cell 37, 767). The infusion of HA tag to the target protein allows easy detection of the recombinant protein with an antibody that recognizes the HA epitope.

[0135] The plasmid construction strategy is described as follows:

[0136] The DNA sequence encoding for HSATU68, ATCC # 97334, was constructed by PCR using two primers: the 5' primer 5' GTCCAAGCTTGCCACCATGGAGTTGAGGAAGTAC 3' (SEQ ID NO:5) and contains a HindIII site followed by 18 nucleotides of HSATU68 coding sequence starting from the initiation codon (underlined); the 3' sequence 5' CTGCTCGAGTCAAGCGTAGTCTGGGACGTCGTATGGGTAGCACAAGCCCGAG TAGGA 3' (SEQ ID NO:6) contains complementary sequences to an XhoI site, translation stop codon, HA tag and the last 15 nucleotides of the HSATU68 coding sequence (not including the stop codon). Therefore, the PCR product contains a HindIII site HSATU68 coding sequence followed by HA tag fused in frame, a translation termination stop codon next to the HA tag, and an XhoI site. The PCR amplified DNA fragment and the vector, pcDNAI/Amp, were digested with HindIII and XhoI restriction enzyme and ligated. The ligation mixture was transformed into *E. coli* strain SURE (Stratagene Cloning Systems, La Jolla, Calif. 92037) the transformed culture was plated on ampicillin media plates and resistant colonies were selected. Plasmid DNA was isolated from transformants and examined by restriction analysis for the presence of the correct fragment. For expression of the recombinant HSATU68, COS cells were transfected with the expression vector by DEAE-DEXTRAN method (J. Sambrook, E. Fritsch, T. Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, (1989)). The expression of the HSATU68 HA protein was detected by radiolabelling and immunoprecipitation method (E. Harlow, D. Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, (1988)). Cells were labelled for 8 hours with ³⁵S-cysteine two days post transfection. Culture media were then collected and cells were lysed with detergent (RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 1% NP-40, 0.5% DOC, 50 mM Tris, pH 7.5) (Wilson, I. et al., Id. 37:767 (1984)). Both cell lysate and culture media were precipitated with a HA specific monoclonal antibody. Proteins precipitated were analyzed on 15% SDS-PAGE gels.

EXAMPLE 3

Cloning and Expression of HSATU68 Using the Baculovirus Expression System

[0137] The DNA sequence encoding the full length HSATU68 protein, ATCC # 97334, was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene:

[0138] The 5' primer has the sequence 5' CGGGATC-CCTCCCATGGAGTTGAGGAAGTAC 3' (SEQ ID NO:7)

and contains a BamHI restriction enzyme site followed by 5 nucleotides resembling an efficient signal for the initiation of translation in eukaryotic cells (J. Mol. Biol. 1987, 196, 947-950, Kozak, M.), and just behind the first 6 nucleotides of the HSATU68 gene (the initiation codon for translation is "ATG"). The 3' primer has the sequence 5' CGGGATC-CCGCTCACAAAGCCCGAGTAGGA 3' (SEQ ID NO:8) and contains the cleavage site for the restriction endonuclease BamHI and 18 nucleotides complementary to the 3' non-translated sequence of the HSATU68 gene. The amplified sequences were isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Calif.). The fragment was then digested with the endonuclease BamHI and purified as described above. This fragment is designated F2.

[0139] The vector pRG1 (modification of pVL941 vector, discussed below) is used for the expression of the HSATU68 protein using the baculovirus expression system (for review see: Summers, M. D. and Smith, G. E. 1987, A manual of methods for baculovirus vectors and insect cell culture procedures, Texas Agricultural Experimental Station Bulletin No. 1555). This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by the recognition sites for the restriction endonuclease BamHI. The polyadenylation site of the simian virus SV40 is used for efficient polyadenylation. For an easy selection of recombinant viruses the beta-galactosidase gene from *E. coli* is inserted in the same orientation as the polyhedrin promoter followed by the polyadenylation signal of the polyhedrin gene. The polyhedrin sequences are flanked at both sides by viral sequences for the cell-mediated homologous recombination of co-transfected wild-type viral DNA. Many other baculovirus vectors could be used in place of pRG1 such as pAc373, pVL941 and pAcIM1 (Luckow, V. A. and Summers, M. D., Virology, 170:31-39).

[0140] The plasmid was digested with the restriction enzyme BamHI and then dephosphorylated using calf intestinal phosphatase by procedures known in the art. The DNA was then isolated from a 1% agarose gel as described above. This vector DNA is designated V2.

[0141] Fragment F2 and the dephosphorylated plasmid V2 were ligated with T4 DNA ligase. *E. coli* HB101 cells were then transformed and bacteria identified that contained the plasmid (pBacHSATU68) with the HSATU68 gene using the enzyme BamHI. The sequence of the cloned fragment was confirmed by DNA sequencing.

[0142] 5 μ g of the plasmid pBacHSATU68 were co-transfected with 1.0 μ g of a commercially available linearized baculovirus ("BaculoGold baculovirus DNA", Pharmingen, San Diego, Calif.) using the lipofection method (Felgner et al. Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987)).

[0143] 1 μ g of BaculoGold virus DNA and 5 μ g of the plasmid pBacHSATU68 were mixed in a sterile well of a microtiter plate containing 50 μ l of serum free Grace's medium (Life Technologies Inc., Gaithersburg, Md.). Afterwards 10 μ l Lipofectin plus 90 μ l Grace's medium were added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture was added drop wise to the Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace' medium without serum.

The plate was rocked back and forth to mix the newly added solution. The plate was then incubated for 5 hours at 27° C. After 5 hours the transfection solution was removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum was added. The plate was put back into an incubator and cultivation continued at 27° C. for four days.

[0144] After four days the supernatant was collected and a plaque assay performed similar as described by Summers and Smith (supra). As a modification an agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) was used which allows an easy isolation of blue stained plaques. (A detailed description of a "plaque assay" can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10).

[0145] Four days after the serial dilution, the viruses were added to the cells and blue stained plaques were picked with the tip of an Eppendorf pipette. The agar containing the recombinant viruses was then resuspended in an Eppendorf tube containing 200 μ l of Grace's medium. The agar was removed by a brief centrifugation and the supernatant containing the recombinant baculoviruses was used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes were harvested and then stored at 4° C.

[0146] Sf9 cells were grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells were infected with the recombinant baculovirus V-HSATU68 at a multiplicity of infection (MOI) of 2. Six hours later the medium was removed and replaced with SF900 II medium minus methionine and cysteine (Life Technologies Inc., Gaithersburg). 42 hours later 5 μ Ci of ³⁵S-methionine and 5 μ Ci ³⁵S cysteine (Amersham) were added. The cells were further incubated for 16 hours before they were harvested by centrifugation and the labelled proteins visualized by SDS-PAGE and autoradiography.

EXAMPLE 4

Expression via Gene Therapy

[0147] Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin, is added. This is then incubated at 37° C. for approximately one week. At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

[0148] pMV-7 (Kirschmeier, P. T. et al, DNA, 7:219-25 (1988) flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

[0149] The cDNA encoding a polypeptide of the present invention is amplified using PCR primers which correspond to the 5' and 3' end sequences respectively. The 5' primer contains an EcoRI site and the 3' primer contains a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is used to transform bacteria HB101, which are then plated onto agar-containing kanamycin for the purpose of confirming that the vector had the gene of interest properly inserted.

[0150] The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells are transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

[0151] Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his.

[0152] The engineered fibroblasts are then injected into the host. The fibroblasts now produce the protein product.

[0153] Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, within the scope of the appended claims, the invention may be practiced otherwise than as particularly described.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 9

<210> SEQ ID NO 1

<211> LENGTH: 1876

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (173)..(1420)

<400> SEQUENCE: 1

```

cctgaaggga gagcagggag agagaggaca gtggccagag agggctcttg gcaactggagg      60
gacgctcttc ttcctgccca ggggtccctg ggccgatggg atcacgcaga agaatgcgag      120
agaagcagcc ttgagaagg gaagtcacta tcccagagcc cagactgagc gg atg gag      178
                                   Met Glu
                                   1

ttg agg aag tac ggc cct gga aga ctg gcg ggg aca gtt ata gga gga      226
Leu Arg Lys Tyr Gly Pro Gly Arg Leu Ala Gly Thr Val Ile Gly Gly
      5              10              15

gct gct cag agt aaa tca cag act aaa tca gac tca atc aca aaa gag      274
Ala Ala Gln Ser Lys Ser Gln Thr Lys Ser Asp Ser Ile Thr Lys Glu
      20              25              30

ttc ctg cca ggc ctt tac aca gcc cct tcc tcc ccg ttc ccg ccc tca      322
Phe Leu Pro Gly Leu Tyr Thr Ala Pro Ser Ser Pro Phe Pro Pro Ser
      35              40              45              50

cag gtg agt gac cac caa gtg cta aat gac gcc gag gtt gcc gcc ctc      370
Gln Val Ser Asp His Gln Val Leu Asn Asp Ala Glu Val Ala Ala Leu
      55              60              65

ctg gag aac ttc agc tct tcc tat gac tat gga gaa aac gag agt gac      418
Leu Glu Asn Phe Ser Ser Ser Tyr Asp Tyr Gly Glu Asn Glu Ser Asp
      70              75              80

tcg tgc tgt acc tcc ccg ccc tgc cca cag gac ttc agc ctg aac ttc      466
Ser Cys Cys Thr Ser Pro Pro Cys Pro Gln Asp Phe Ser Leu Asn Phe
      85              90              95

gac cgg gcc ttc ctg cca gcc ctc tac agc ctc ctc ttt ctg ctg ggg      514

```

-continued

Asp	Arg	Ala	Phe	Leu	Pro	Ala	Leu	Tyr	Ser	Leu	Leu	Phe	Leu	Leu	Gly	
100						105				110						
ctg	ctg	ggc	aac	ggc	gcg	gtg	gca	gcc	gtg	ctg	ctg	agc	cgg	cgg	aca	562
Leu	Leu	Gly	Asn	Gly	Ala	Val	Ala	Ala	Val	Leu	Leu	Ser	Arg	Arg	Thr	
115					120					125					130	
gcc	ctg	agc	agc	acc	gac	acc	ttc	ctg	ctc	cac	cta	gct	gta	gca	gac	610
Ala	Leu	Ser	Ser	Thr	Asp	Thr	Phe	Leu	Leu	His	Leu	Ala	Val	Ala	Asp	
				135						140					145	
acg	ctg	ctg	gtg	ctg	aca	ctg	ccg	ctc	tgg	gca	gtg	gac	gct	gcc	gtc	658
Thr	Leu	Leu	Val	Leu	Thr	Leu	Pro	Leu	Trp	Ala	Val	Asp	Ala	Ala	Val	
				150					155						160	
cag	tgg	gtc	ttt	ggc	tct	ggc	ctc	tgc	aaa	gtg	gca	ggg	gcc	ctc	ttc	706
Gln	Trp	Val	Phe	Gly	Ser	Gly	Leu	Cys	Lys	Val	Ala	Gly	Ala	Leu	Phe	
		165					170					175				
aac	atc	aac	ttc	tac	gca	gga	gcc	ctc	ctg	ctg	gcc	tgc	atc	agc	ttt	754
Asn	Ile	Asn	Phe	Tyr	Ala	Gly	Ala	Leu	Leu	Leu	Ala	Cys	Ile	Ser	Phe	
		180				185						190				
gac	cgc	tac	ctg	aac	ata	gtt	cat	gcc	acc	cag	ctc	tac	cgc	cgg	ggg	802
Asp	Arg	Tyr	Leu	Asn	Ile	Val	His	Ala	Thr	Gln	Leu	Tyr	Arg	Arg	Gly	
195					200					205					210	
ccc	ccg	gcc	cgc	gtg	acc	ctc	acc	tgc	ctg	gct	gtc	tgg	ggg	ctc	tgc	850
Pro	Pro	Ala	Arg	Val	Thr	Leu	Thr	Cys	Leu	Ala	Val	Trp	Gly	Leu	Cys	
				215					220						225	
ctg	ctt	ttc	gcc	ctc	cca	gac	ttc	atc	ttc	ctg	tcg	gcc	cac	cac	gac	898
Leu	Leu	Phe	Ala	Leu	Pro	Asp	Phe	Ile	Phe	Leu	Ser	Ala	His	His	Asp	
			230					235						240		
gag	cgc	ctc	aac	gcc	acc	cac	tgc	caa	tac	aac	ttc	cca	cag	gtg	ggc	946
Glu	Arg	Leu	Asn	Ala	Thr	His	Cys	Gln	Tyr	Asn	Phe	Pro	Gln	Val	Gly	
		245					250					255				
cgc	acg	gct	ctg	cgg	gtg	ctg	cag	ctg	gtg	gct	ggc	ttt	ctg	ctg	ccc	994
Arg	Thr	Ala	Leu	Arg	Val	Leu	Gln	Leu	Val	Ala	Gly	Phe	Leu	Leu	Pro	
		260				265					270					
ctg	ctg	gtc	atg	gcc	tac	tgc	tat	gcc	cac	atc	ctg	gcc	gtg	ctg	ctg	1042
Leu	Leu	Val	Met	Ala	Tyr	Cys	Tyr	Ala	His	Ile	Leu	Ala	Val	Leu	Leu	
275					280					285					290	
gtt	tcc	agg	ggc	cag	cgg	cgc	ctg	cgg	gcc	atg	cgg	ctg	gtg	gtg	gtg	1090
Val	Ser	Arg	Gly	Gln	Arg	Arg	Leu	Arg	Ala	Met	Arg	Leu	Val	Val	Val	
			295						300					305		
gtc	gtg	gtg	gcc	ttt	gcc	ctc	tgc	tgg	acc	ccc	tat	cac	ctg	gtg	gtg	1138
Val	Val	Val	Ala	Phe	Ala	Leu	Cys	Trp	Thr	Pro	Tyr	His	Leu	Val	Val	
			310					315					320			
ctg	gtg	gac	atc	ctc	atg	gac	ctg	ggc	gct	ttg	gcc	cgc	aac	tgt	ggc	1186
Leu	Val	Asp	Ile	Leu	Met	Asp	Leu	Gly	Ala	Leu	Ala	Arg	Asn	Cys	Gly	
		325					330					335				
cga	gaa	agc	agg	gta	gac	gtg	gcc	aag	tcg	gtc	acc	tca	ggc	ctg	ggc	1234
Arg	Glu	Ser	Arg	Val	Asp	Val	Ala	Lys	Ser	Val	Thr	Ser	Gly	Leu	Gly	
		340				345					350					
tac	atg	cac	tgc	tgc	ctc	aac	ccg	ctg	ctc	tat	gcc	ttt	gta	ggg	gtc	1282
Tyr	Met	His	Cys	Cys	Leu	Asn	Pro	Leu	Leu	Tyr	Ala	Phe	Val	Gly	Val	
355					360					365					370	
aag	ttc	cgg	gag	cgg	atg	tgg	atg	ctg	ctc	ttg	cgc	ctg	ggc	tgc	ccc	1330
Lys	Phe	Arg	Glu	Arg	Met	Trp	Met	Leu	Leu	Leu	Arg	Leu	Gly	Cys	Pro	
			375					380						385		
aac	cag	aga	ggg	ctc	cag	agg	cag	cca	tcg	tct	tcc	cgc	cgg	gat	tca	1378
Asn	Gln	Arg	Gly	Leu	Gln	Arg	Gln	Pro	Ser	Ser	Ser	Arg	Arg	Asp	Ser	
			390					395						400		
tcc	tgg	tct	gag	acc	tca	gag	gcc	tcc	tac	tcg	ggc	ttg	tga			1420

-continued

```

Ser Trp Ser Glu Thr Ser Glu Ala Ser Tyr Ser Gly Leu
  405                      410                      415

ggccggaatc cgggctcccc ttctgcccac agtctgactt ccccgcatc caggctctc 1480
cctccctctg cgggtctctg ctctcccaa tctctctgct cccgggactc actggcagcc 1540
ccagcaccac caggctctccc ggaagccac cctcccagct ctgaggactg caccattgct 1600
gctccttagc tgccaagccc catcctgccg cccgaggtgg ctgcctggag cccactgcc 1660
cttctcattt ggaaactaaa acttcatctt cccaagtgc ggggagtaca aggcattggc 1720
tagagggtgc tgccccatga agccacagcc caggcctcca gctcagcagt gactgtggcc 1780
atggtcccca agacctctat atttggtctt ttatTTTTTat gtctaaaaatc ctgcttaaaa 1840
cttttcaata aacaagatcg tcaggaaaaa aaaaaa 1876

```

<210> SEQ ID NO 2

<211> LENGTH: 415

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

```

Met Glu Leu Arg Lys Tyr Gly Pro Gly Arg Leu Ala Gly Thr Val Ile
  1              5              10              15

Gly Gly Ala Ala Gln Ser Lys Ser Gln Thr Lys Ser Asp Ser Ile Thr
      20              25              30

Lys Glu Phe Leu Pro Gly Leu Tyr Thr Ala Pro Ser Ser Pro Phe Pro
      35              40              45

Pro Ser Gln Val Ser Asp His Gln Val Leu Asn Asp Ala Glu Val Ala
      50              55              60

Ala Leu Leu Glu Asn Phe Ser Ser Ser Tyr Asp Tyr Gly Glu Asn Glu
      65              70              75              80

Ser Asp Ser Cys Cys Thr Ser Pro Pro Cys Pro Gln Asp Phe Ser Leu
      85              90              95

Asn Phe Asp Arg Ala Phe Leu Pro Ala Leu Tyr Ser Leu Leu Phe Leu
      100             105             110

Leu Gly Leu Leu Gly Asn Gly Ala Val Ala Ala Val Leu Leu Ser Arg
      115             120             125

Arg Thr Ala Leu Ser Ser Thr Asp Thr Phe Leu Leu His Leu Ala Val
      130             135             140

Ala Asp Thr Leu Leu Val Leu Thr Leu Pro Leu Trp Ala Val Asp Ala
      145             150             155             160

Ala Val Gln Trp Val Phe Gly Ser Gly Leu Cys Lys Val Ala Gly Ala
      165             170             175

Leu Phe Asn Ile Asn Phe Tyr Ala Gly Ala Leu Leu Leu Ala Cys Ile
      180             185             190

Ser Phe Asp Arg Tyr Leu Asn Ile Val His Ala Thr Gln Leu Tyr Arg
      195             200             205

Arg Gly Pro Pro Ala Arg Val Thr Leu Thr Cys Leu Ala Val Trp Gly
      210             215             220

Leu Cys Leu Leu Phe Ala Leu Pro Asp Phe Ile Phe Leu Ser Ala His
      225             230             235             240

His Asp Glu Arg Leu Asn Ala Thr His Cys Gln Tyr Asn Phe Pro Gln
      245             250             255

Val Gly Arg Thr Ala Leu Arg Val Leu Gln Leu Val Ala Gly Phe Leu

```

-continued

260	265	270
Leu Pro Leu Leu Val Met Ala Tyr Cys Tyr Ala His Ile Leu Ala Val		
275	280	285
Leu Leu Val Ser Arg Gly Gln Arg Arg Leu Arg Ala Met Arg Leu Val		
290	295	300
Val Val Val Val Val Ala Phe Ala Leu Cys Trp Thr Pro Tyr His Leu		
305	310	315
Val Val Leu Val Asp Ile Leu Met Asp Leu Gly Ala Leu Ala Arg Asn		
325	330	335
Cys Gly Arg Glu Ser Arg Val Asp Val Ala Lys Ser Val Thr Ser Gly		
340	345	350
Leu Gly Tyr Met His Cys Cys Leu Asn Pro Leu Leu Tyr Ala Phe Val		
355	360	365
Gly Val Lys Phe Arg Glu Arg Met Trp Met Leu Leu Leu Arg Leu Gly		
370	375	380
Cys Pro Asn Gln Arg Gly Leu Gln Arg Gln Pro Ser Ser Ser Arg Arg		
385	390	395
Asp Ser Ser Trp Ser Glu Thr Ser Glu Ala Ser Tyr Ser Gly Leu		
405	410	415

<210> SEQ ID NO 3
 <211> LENGTH: 29
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Contains a BamHI restriction enzyme site

<400> SEQUENCE: 3

cgggatcctc catggagttg aggaagtac

29

<210> SEQ ID NO 4
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Contains complementary sequences to a BamHI site

<400> SEQUENCE: 4

ggcggatccc gctcacaagc ccgagtagga

30

<210> SEQ ID NO 5
 <211> LENGTH: 34
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Contains a HindIII site

<400> SEQUENCE: 5

gtccaagctt gccaccatgg agttgaggaa gtac

34

<210> SEQ ID NO 6
 <211> LENGTH: 57
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Contains complementary sequences to a XhoI site, translation stop codon, and an HA tag

<400> SEQUENCE: 6

-continued

ctgctcgagt caagcgtagt ctgggacgtc gtagggtag cacaagcccg agtagga 57

<210> SEQ ID NO 7
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Contains a BamHI restriction enzyme site
followed by 5 nucleotides resembling an efficient signal for the
initiation of translation in eukaryotic cells (J. Mol. Biol. 1987,
196, 947-950, Kozak, M.)

<400> SEQUENCE: 7

cgggatccct cccatggagt tgaggaagta c 31

<210> SEQ ID NO 8
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Contains the cleavage site for the restriction
endonuclease BamHI

<400> SEQUENCE: 8

cgggatcccg ctcacaagcc cgagtagga 29

<210> SEQ ID NO 9
<211> LENGTH: 353
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

Glu Ser Asp Ser Phe Glu Asp Phe Trp Lys Gly Glu Asp Leu Ser Asn
1 5 10 15

Tyr Ser Tyr Ser Ser Thr Leu Pro Pro Phe Leu Leu Asp Ala Ala Pro
20 25 30

Cys Glu Pro Glu Ser Leu Glu Ile Asn Lys Tyr Phe Val Val Ile Ile
35 40 45

Tyr Ala Leu Val Phe Leu Leu Ser Leu Leu Gly Asn Ser Leu Val Met
50 55 60

Leu Val Ile Leu Tyr Ser Arg Val Gly Arg Ser Val Thr Asp Val Tyr
65 70 75 80

Leu Leu Asn Leu Ala Leu Ala Asp Leu Leu Phe Ala Leu Thr Leu Pro
85 90 95

Ile Trp Ala Ala Ser Lys Val Asn Gly Trp Ile Phe Gly Thr Phe Leu
100 105 110

Cys Lys Val Val Ser Leu Leu Lys Glu Val Asn Phe Tyr Ser Gly Ile
115 120 125

Leu Leu Leu Ala Cys Ile Ser Val Asp Arg Tyr Leu Ala Ile Val His
130 135 140

Ala Thr Arg Thr Leu Thr Gln Lys Arg Tyr Leu Val Lys Phe Ile Cys
145 150 155 160

Leu Ser Ile Trp Gly Leu Ser Leu Leu Leu Ala Leu Pro Val Leu Leu
165 170 175

Phe Arg Arg Thr Val Tyr Ser Ser Asn Val Ser Pro Ala Cys Tyr Glu
180 185 190

Asp Met Gly Asn Asn Thr Ala Asn Trp Arg Met Leu Leu Arg Ile Leu

-continued

195	200	205
Pro Gln Ser Phe Gly Phe Ile Val Pro Leu Leu Ile Met Leu Phe Cys		
210	215	220
Tyr Gly Phe Thr Leu Arg Thr Leu Phe Lys Ala His Met Gly Gln Lys		
225	230	235
His Arg Ala Met Arg Val Ile Phe Ala Val Val Leu Ile Phe Leu Leu		
245	250	255
Cys Trp Leu Pro Tyr Asn Leu Val Leu Leu Ala Asp Thr Leu Met Arg		
260	265	270
Thr Gln Val Ile Gln Glu Thr Cys Glu Arg Arg Asn His Ile Asp Arg		
275	280	285
Ala Leu Asp Ala Thr Glu Ile Leu Gly Ile Leu His Ser Cys Leu Asn		
290	295	300
Pro Leu Ile Tyr Ala Phe Ile Gly Gln Lys Phe Arg His Gly Leu Leu		
305	310	315
Lys Ile Leu Ala Ile His Gly Leu Ile Ser Lys Asp Ser Leu Pro Lys		
325	330	335
Asp Ser Arg Pro Ser Phe Val Gly Ser Ser Ser Gly His Thr Ser Thr		
340	345	350
Thr		

What is claimed is:

1. An isolated polynucleotide comprising a polynucleotide having at least 70% identity to a member selected from the group consisting of:

- (a) a polynucleotide encoding a polypeptide comprising amino acid residues 1 to 415 of SEQ ID NO:2;
- (b) a polynucleotide which is complementary to the polynucleotide of (a);
- (c) a polynucleotide comprising at least 30 bases of the polynucleotide of (a) or (b);
- (d) polynucleotide comprising nucleotides 1 to 1866 of SEQ ID NO:1;
- (e) polynucleotide comprising nucleotides 173 to 1477 of SEQ ID NO:1;
- (f) a polynucleotide encoding the polypeptide encoded by the complete HSATU68 cDNA contained in ATCC Deposit No. 97334;
- (g) a polynucleotide which is complementary to the polynucleotide of (f); and
- (h) a polynucleotide comprising at least 30 bases of the polynucleotide of (f) or (g).

2. The polynucleotide of claim 1 wherein the polynucleotide is DNA.

3. The polynucleotide of claim 2 wherein said polynucleotide encodes a polypeptide comprising amino acid residues 1 to 415 of SEQ ID NO:2.

4. A vector comprising the DNA of claim 2.

5. A host cell comprising the vector of claim 4.

6. A process for producing a polypeptide comprising:

expressing from the host cell of claim 5 the polypeptide encoded by said DNA.

7. A process for producing cell comprising:

transforming or transfecting the cells with the vector of claim 4 to thereby express a polypeptide encoded by the human cDNA contained in said vector.

8. A polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) a polypeptide which is at least 70% identical to amino acid residues 1 to 415 of SEQ ID NO:2; and
- (b) a polypeptide comprising at least 30 amino acid residues of the polypeptide of (a).

9. An antibody that specifically binds the polypeptide of claim 8.

10. An agonist to the polypeptide of claim 8.

11. An antagonist to the polypeptide of claim 8.

12. A method for the treatment of a patient having need to activate a G-protein chemokine receptor comprising: administering to the patient a therapeutically effective amount of the compound of claim 10.

13. A method for the treatment of a patient having need to inhibit a G-protein chemokine receptor comprising: administering to the patient a therapeutically effective amount of the compound of claim 11.

14. The method of claim 12 wherein said compound is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said agonist and expressing said agonist in vivo.

15. The method of claim 13 wherein said compound is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said antagonist and expressing said antagonist in vivo.

16. A method for identifying compounds which bind to and activate or inhibit the polypeptide of claim 8 comprising:

contacting a cell expressing on the surface thereof said polypeptide, said polypeptide being associated with a second compound capable of providing a detectable signal in response to the binding of a compound to said receptor polypeptide, with a compound under conditions sufficient to permit binding of the compound to the polypeptide; and

identifying if the compound is an effective agonist or antagonist by detecting the signal produced by said second component.

17. A process for diagnosing a disease or a susceptibility to a disease related to an activity of the polypeptide of claim

8 comprising determining a mutation in the nucleic acid sequence encoding said polypeptide, wherein said activity is an under-expression, an over-expression, an under-activity, or an over-activity.

18. The polypeptide of claim 8 wherein the polypeptide is a soluble fragment of the polypeptide and is capable of binding a ligand for the receptor.

19. A diagnostic process comprising:

analyzing for the presence of the polypeptide of claim 18 in a sample derived from a host.

* * * * *